MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Merck & Co., Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$143.63−2.32 (-1.59%)
Close on Oct 19, 2026
- Market cap
- $354.77B
- P/E (TTM)
- 114.9
- Dividend yield
- 2.28%
Merck & Co., Inc. revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical | $14.76B | $14.35B | $14.84B | $15.61B | $14.05B | $13.64B | $14.04B | $14.94B | $14.41B | $14.01B | $13.14B | $14.26B | 88.9% | +5.1% |
| Animal Health | $1.78B | $1.79B | $1.51B | $1.62B | $1.65B | $1.59B | $1.40B | $1.49B | $1.48B | $1.51B | $1.28B | $1.40B | 10.7% | +7.8% |
By product or service
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $9.37B | $9.16B | $9.14B | $10.01B | $8.84B | $8.52B | $8.19B | $8.74B | $7.88B | $7.48B | $7.09B | $7.72B | 56.4% | +6.0% |
| Non-US | $7.17B | $7.11B | $7.24B | $7.23B | $6.87B | $6.80B | $7.27B | $7.72B | $8.04B | $8.11B | $7.33B | $8.05B | 43.2% | +4.4% |
| Europe, Middle East and Africa | $3.92B | $3.89B | $3.79B | $3.68B | $3.66B | $3.45B | $3.38B | $3.58B | $3.52B | $3.56B | $3.28B | $3.33B | 23.6% | +7.1% |
| Latin America | $875.00M | $874.00M | $854.00M | $905.00M | $859.00M | $792.00M | $868.00M | $936.00M | $858.00M | $796.00M | $788.00M | $895.00M | 5.3% | +1.9% |
| Asia Pacific (other than China and Japan) | $820.00M | $738.00M | $745.00M | $764.00M | $785.00M | $689.00M | $764.00M | $823.00M | $748.00M | $724.00M | $750.00M | $781.00M | 4.9% | +4.5% |
| Other | $640.00M | $679.00M | $781.00M | $798.00M | $595.00M | $701.00M | $701.00M | $624.00M | $612.00M | $621.00M | $599.00M | $469.00M | 3.9% | +7.6% |
| Japan | $577.00M | $555.00M | $704.00M | $712.00M | $626.00M | $669.00M | $835.00M | $938.00M | $686.00M | $821.00M | $650.00M | $1.08B | 3.5% | -7.8% |
| China | $408.00M | $390.00M | $386.00M | $405.00M | $446.00M | $702.00M | $888.00M | $1.02B | $1.82B | $1.77B | $1.48B | $1.69B | 2.5% | -8.5% |
| Intl | – | – | – | – | – | – | – | – | – | $8.30B | $7.54B | $8.25B | – | – |
From the segment and revenue-disaggregation notes of Merck's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.